meszaros

CLF could face a 34% rise.

Long
NYSE:CLF   Cleveland-Cliffs Inc.
CLF could face a 34% rise. The analysis includes two strategies. One is a pure ATR strategy and the other is a symmetric wave sequence strategy. When we start using the ATR strategy, the first step is to determine the value of the day (D1 ATR) and the week (W1ATR). These are typical levels that price movements use as support, resistance or reflective axes. In many cases they can be used as a target price or stop level, but can also be used as a trend changing strategy. In our case it is used to determine the end of a correction. Using a strategy on its own is not enough, as it has a hit rate of only 50% (ideally), to be profitable in the long run, it is necessary to tilt the hit rate to our side, at least between 65-75%. Because in a 2RR bet, where RR is the Risk-Reward ratio, only in this case can our average profit be higher than our average loss. In short, this MM is the key to success. Back to the analysis. The figure shows the W1ATR distance. I have described this many times, but it bears repeating. This distance(white square height) represents the 1-week size of the price movement. In other words, the average value of the 14-week movement. The top and bottom of these levels are representative levels at which the movement of the wave sequences can change. This is where the second strategy comes in. This is none other than the wave sequence. From the figure, it can be seen that the upper level of W1ATR (narrow white square) and the lower level (narrow white square) have developed similar corrections. This predicts that wave sequences of similar size are built up for these two levels (top and bottom). In the case where this set of rules is true, the determination of the next target price is easy, since we only need to consider the amplitude of the symmetrically generated waves. SUMMARY : CLF has completed the correction. I expect a rise from the current level(21.87 usd). Next target price : 29.64 usd.


Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.